[go: up one dir, main page]

CA2261680C - Fluorine-containing 1,4-disubstituted piperidine derivatives - Google Patents

Fluorine-containing 1,4-disubstituted piperidine derivatives Download PDF

Info

Publication number
CA2261680C
CA2261680C CA002261680A CA2261680A CA2261680C CA 2261680 C CA2261680 C CA 2261680C CA 002261680 A CA002261680 A CA 002261680A CA 2261680 A CA2261680 A CA 2261680A CA 2261680 C CA2261680 C CA 2261680C
Authority
CA
Canada
Prior art keywords
compound
hydroxy
piperidin
pharmaceutically acceptable
difluorocyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002261680A
Other languages
English (en)
French (fr)
Other versions
CA2261680A1 (en
Inventor
Yoshimi Tsuchiya
Takashi Nomoto
Hirokazu Ohsawa
Kumiko Kawakami
Kenji Ohwaki
Masaru Nishikibe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
Banyu Phamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd
Publication of CA2261680A1 publication Critical patent/CA2261680A1/en
Application granted granted Critical
Publication of CA2261680C publication Critical patent/CA2261680C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002261680A 1996-08-01 1997-07-28 Fluorine-containing 1,4-disubstituted piperidine derivatives Expired - Fee Related CA2261680C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP8/219436 1996-08-01
JP21943696 1996-08-01
JP5397997 1997-02-21
JP9/53979 1997-02-21
PCT/JP1997/002600 WO1998005641A1 (en) 1996-08-01 1997-07-28 Fluorinated 1,4-disubstituted piperidine derivatives

Publications (2)

Publication Number Publication Date
CA2261680A1 CA2261680A1 (en) 1998-02-12
CA2261680C true CA2261680C (en) 2005-03-08

Family

ID=26394715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002261680A Expired - Fee Related CA2261680C (en) 1996-08-01 1997-07-28 Fluorine-containing 1,4-disubstituted piperidine derivatives

Country Status (29)

Country Link
US (2) US5948792A (es)
EP (1) EP0930298B1 (es)
JP (1) JP3063164B2 (es)
KR (1) KR20000022214A (es)
CN (1) CN1226888A (es)
AR (3) AR008272A1 (es)
AT (1) ATE229941T1 (es)
AU (1) AU716050B2 (es)
BG (1) BG103114A (es)
BR (1) BR9711108A (es)
CA (1) CA2261680C (es)
CO (1) CO4960641A1 (es)
CZ (1) CZ33199A3 (es)
DE (1) DE69718026T2 (es)
EE (1) EE9900038A (es)
ES (1) ES2188961T3 (es)
HR (1) HRP970426A2 (es)
HU (1) HUP9902381A3 (es)
ID (1) ID17259A (es)
IL (1) IL127685A0 (es)
IS (1) IS4960A (es)
NO (1) NO990472D0 (es)
NZ (1) NZ333842A (es)
PE (1) PE92198A1 (es)
PL (1) PL331431A1 (es)
SK (1) SK12299A3 (es)
TR (2) TR199900204T2 (es)
WO (1) WO1998005641A1 (es)
YU (1) YU1299A (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
AU4194500A (en) * 1999-04-08 2000-11-14 Banyu Pharmaceutical Co., Ltd. Diastereoselective preparation of michael adducts
WO2000066579A1 (en) * 1999-04-28 2000-11-09 Banyu Pharmaceutical Co., Ltd. Processes for the preparation of piperidylmethylpyridine derivatives
WO2001013918A1 (en) * 1999-08-23 2001-03-01 H. Lundbeck A/S Treatment of urinary incontinence
CA2392028C (en) * 1999-12-07 2009-08-18 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
AU2525801A (en) * 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
AU2001271027B2 (en) * 2000-07-11 2005-07-07 Msd K.K. Ester derivatives
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
SK287414B6 (sk) * 2000-12-28 2010-09-07 Laboratorios Almirall, S.A. Chinuklidínové deriváty a kompozície s ich obsahom
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
IL160852A0 (en) * 2001-09-27 2004-08-31 Pharmacia Ab Pharmaceutical compositions for the treatment of urinary disorders
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
HK1079787A1 (zh) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
EP1562599A1 (en) * 2002-10-29 2005-08-17 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds as muscarinic receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
WO2004056811A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) * 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615634B1 (en) 2003-04-10 2007-05-16 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070021487A1 (en) 2003-04-11 2007-01-25 Mohammad Salman Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
JP2007524641A (ja) 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
NZ548128A (en) * 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
US20080319002A1 (en) * 2004-06-16 2008-12-25 Ranbaxy Laboratories Limited Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
US20080262075A1 (en) * 2004-08-19 2008-10-23 Ranbaxy Laboratories Limited Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
US20080280883A1 (en) * 2004-09-24 2008-11-13 Mohammad Salman Muscarinic Receptor Antagonists
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN101094847B (zh) 2004-11-02 2011-06-15 Msdk.K.公司 芳氧基取代的苯并咪唑衍生物
EP1828174A1 (en) * 2004-11-19 2007-09-05 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
JP4990783B2 (ja) * 2005-09-30 2012-08-01 Ｍｓｄ株式会社 ２−ヘテロアリール置換インドール誘導体
US20090131410A1 (en) * 2005-10-05 2009-05-21 Naresh Kumar 3-azabicyclooctane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
KR101517574B1 (ko) 2007-09-07 2015-05-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 길항제로서 유용한 구아니딘을 함유하는 화합물
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
AU700837B2 (en) * 1995-04-28 1999-01-14 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
AU7145996A (en) * 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives

Also Published As

Publication number Publication date
ATE229941T1 (de) 2003-01-15
PE92198A1 (es) 1999-01-09
CA2261680A1 (en) 1998-02-12
EP0930298B1 (en) 2002-12-18
ES2188961T3 (es) 2003-07-01
CZ33199A3 (cs) 1999-07-14
US5948792A (en) 1999-09-07
IS4960A (is) 1999-01-29
TR200001482T2 (tr) 2000-11-21
PL331431A1 (en) 1999-07-19
DE69718026D1 (de) 2003-01-30
AU716050B2 (en) 2000-02-17
US6040449A (en) 2000-03-21
TR199900204T2 (xx) 2000-01-21
ID17259A (id) 1997-12-11
CN1226888A (zh) 1999-08-25
SK12299A3 (en) 2000-05-16
IL127685A0 (en) 1999-10-28
NO990472L (no) 1999-02-01
EP0930298A1 (en) 1999-07-21
HRP970426A2 (en) 1998-08-31
HUP9902381A2 (hu) 1999-11-29
KR20000022214A (ko) 2000-04-25
AU3635197A (en) 1998-02-25
NO990472D0 (no) 1999-02-01
JP3063164B2 (ja) 2000-07-12
NZ333842A (en) 2001-05-25
WO1998005641A1 (en) 1998-02-12
EP0930298A4 (en) 2000-06-07
CO4960641A1 (es) 2000-09-25
AR017021A1 (es) 2001-08-22
AR016877A2 (es) 2001-08-01
BR9711108A (pt) 1999-08-17
BG103114A (en) 1999-11-30
AR008272A1 (es) 1999-12-29
HUP9902381A3 (en) 2000-06-28
DE69718026T2 (de) 2003-07-10
EE9900038A (et) 1999-08-16
YU1299A (sh) 2002-03-18

Similar Documents

Publication Publication Date Title
CA2261680C (en) Fluorine-containing 1,4-disubstituted piperidine derivatives
JP7787812B2 (ja) 置換大環状化合物および関連する治療方法
JPWO1998005641A1 (ja) 含フッ素１，４−ジ置換ピペリジン誘導体
CA2218479C (en) 1,4-di-substituted piperidine derivatives
EP0863141B1 (en) Substituted heteroaromatic derivatives
US8030502B2 (en) Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds
JPH07505648A (ja) アザサイクリック化合物
JP2006512408A5 (es)
CH666033A5 (de) 1,4-dihydropyridinderivate und deren salze und hydrate, verfahren zur herstellung dieser verbindungen und solche verbindungen enthaltende pharmazeutische praeparate.
WO1997045414A1 (en) 1,4-disubstituted piperidine derivatives
DE69522332T2 (de) 1,4-dihydropyridine als bradykinin antagonisten
JP2007524641A (ja) 置換４−アミノ−１−ベンジルピペリジン化合物
CA2380074C (en) Novel amide derivatives
HK1020341A (en) Fluorinated 1, 4-disubstituted piperidine derivatives
JP3282618B2 (ja) 含フッ素１，４−ジ置換ピペリジン誘導体の新規製造中間体
JP3282617B2 (ja) 含フッ素１，４−ジ置換ピペリジン誘導体の新規製造中間体
MXPA99000965A (es) Derivados de piperidina 1,4-disubstituidos que contienen fluor
US20040236114A1 (en) Imidazole derivatives as adenosine deaminase inhibitors
KR100339444B1 (ko) 타키키닌길항제로서 유용한 치환된 피롤리딘-3-일-알킬-피페리딘
JP2993124B2 (ja) １，４−ジ置換ピペリジン誘導体
JPWO1997045414A1 (ja) １，４−ジ置換ピペリジン誘導体
JPWO1996033973A1 (ja) １，４−ジ置換ピペリジン誘導体
JPWO1997013766A1 (ja) 置換ヘテロ芳香環誘導体

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed